Dear Editor,

Agranulocytosis induced by sulphonamide or dapsone (44-diaminodiphenylsulphone - DDS) is characterized by a low concentration or absence of granulocytes due to sulfone cytotoxicity effects on bone marrow and mononuclear cells.^[@r1]^

DDS is a structural analogue of para-aminobenzoic acid (PABA) that acts as a competitive inhibitor of the enzyme dihydropteroate synthase in the folate pathway. It has anti-inflammatory, antibacterial, antiprotozoal, and antifungal activities. Used since 1943 to treat leprosy, it is also indicated for the treatment of malaria, rheumatoid arthritis, granuloma annulare, dermatitis herpetiformis, and other vesiculobullous diseases. DDS adverse effects include hemolytic anemia, methemoglobinemia, gastritis, headache, agranulocytosis, hepatitis, peripheral neuropathy, nephrotic syndrome, dapsone syndrome, among others.^[@r1],[@r2]^

DDS is part of the multidrug therapy (MDT) used to treat leprosy. The regimen is a combination of rifampicin (supervised monthly dose of 600mg) and dapsone (supervised monthly dose of 100mg and 100mg/daily) for paucibacillary patients, with the addition of clofazimine (supervised monthly dose of 300mg and 50mg/ daily) for multibacillar patients.^[@r2]^

We report a 61-year-old Caucasian female patient, resident in Juazeiro, state of Bahia, Brazil, complaining of a spot on the right elbow, which appeared 1 year before. Physical examination revealed a single hypochromic patch, approximately 1cm in diameter, with micropapular edges and absent thermal sensitivity. With a diagnosis of tuberculoid leprosy, we started a MDT regimen for paucibacillary leprosy. At day 14 after the first administration, the patient presented with adynamia, exertional dyspnea, normochromic normocytic anemia with anisocytosis, and normal white blood cell (WBC) count. At day 34, she presented with fever, chills, adynamia, oropharyngeal pain, and cutaneous pallor associated with leukopenia with severe neutropenia. We suspended the MDT and, advised by a hematologist, introduced amoxicillin clavulanate, ciprofloxacin, and filgrastim (rHu G-CSF) 300 µg/daily for 5 days.

Serial blood test collection revealed a typical clinical presentation of agranulocytosis ([Table 1](#t1){ref-type="table"}).

###### 

Monitoring of a female patient with leprosy during paucibacillary multidrug therapy

  DATE          06.30.2014        11.06.2014   11.26.2014   11.28.2014   11.30.2014   12.04.2014   01.28.2015   Standards
  ------------- ----------------- ------------ ------------ ------------ ------------ ------------ ------------ -------------
  Period of     Before starting   Day 14       Day 34       Dapsone                                              
  Treatment     treatment with                              Interrup-                                            
  (MDT)         dapsone                                     tion                                                 
  Hemoglobin    11.9              10.9         8.8          8.9          10           9.8          14.5         13-18 (men)
  (g/dL)                                                                                                        12-16
                                                                                                                (women)
  Hematocrit    35.8              32.5         27           27.6         32.6         30.7         42.2         40-52
  (%)                                                                                                           37-47
  WBC count     4400              4000         1520         1000         1090         6300         4700         4000-11000
  (mm^3^)                                                                                                        
  Bands (%)                                                                           13           1            1-5%
  Segmented     \-                74           74           11           10           48           77           50-70%
  (%)                                                                                                            
  Limphocytes   21                22           25           8            84           24           20           20-45%
  (%)                                                                                                            
  Eosinophils   0                 1            1            0            1            0            1            1-4%
  (%)                                                                                                            
  Basophils     0                 1            0            2            0            2            0            0-1%
  (%)                                                                                                            
  Monocytes     2                 2            0            1            5            0            1            2-12%
  (%)                                                                                                            
  Platelets/    211000            225000       212000       285000       324000       315000       206000       140-450 x
  mm^3^                                                                                                         103

After 8 days, the patient showed clinical and laboratorial improvement. Test levels remained normal during 1-month follow-up when we reintroduced the MDT substituting DDS by clofazimine. The patient completed 6 months of MDT.

Agranulocytosis is a rare but serious complication of sulfones caused by the myelotoxic effect of these drugs. An occurrence of 0.2-0.4% has been described in patients treated with dapsone. Although reversible, this infection can lead to sepsis and even death.^[@r3]^

Agranulocytosis is an adverse effect of dapsone manifested as bone marrow suppression, which is caused by the formation of antibodies against neutrophil progenitor cells, decreasing the granulocyte formation. Another possible mechanism is the sensitization to the drug that forms hydroxylamine, a toxic metabolite of dapsone responsible for methemoglobinemia and hemolysis.^[@r3]^

For the treatment of leprosy, the risk of developing DDS-induced agranulocytosis is about 25-33 times higher because of reduced immunity and high dosage of the drug, as compared, for example to the treatment of malaria with an incidence between 1:10,000 and 1: 20,000 is reported. ^[@r2],[@r4]^

According to Silva *et al.* (2009),^[@r1]^ Mishra and Chhetia (2006),^[@r3]^ Bhat and Radhakrishnan (2003),^[@r4]^ Carneiro *et al.* (2011),^[@r5]^ and our case, the patients presented with abrupt symptoms associated with fever, oropharyngeal pain, chills, adynamia, hypotension, tachypnea, and chest pain. All of them, except Mishra and Chhetia (2006),^[@r3]^ showed a significant reduction in WBC counts to values below 1,000 cells/ mm^[@r3]^, with neutropenia below 500 cells/mm^[@r3]^.^[@r4]^

Although Silva *et al.* (2009),^[@r1]^ Mishra and Chhetia (2006),^[@r3]^ and Bhat and Radhakrishnan (2003)^[@r4]^ reported cases in male patients; our report is in agreement with the literature in relation to the female predilection.^[@r5]^ In relation to age, our report agrees Bhat and Radhakrishnan (2003),^[@r4]^ showing a higher incidence around 60 years of age.

According to Mishra and Chhetia (2006),^[@r3]^ Carneiro *et al.* (2011),^[@r5]^ and our report, agranulocytosis occurs between 3 weeks and 3 months after the onset of the MDT.^[@r5]^

In the literature and in our case, patients started MDT to treat agranulocytosis, but DDS had to be discontinued due to side effects. The treatments continued with antibiotic therapy and filgrastim revealing leucometric and clinical improvement in a few days,^[@r5]^ except for the patient followed by Bhat and Radhakrishnan (2003),^[@r4]^ who died.

After clinical improvement, some patients had their MDT altered for ofloxacin, clofazimine, and minocycline, with each drug introduced at 30-day intervals, or for rifampicin and clofazimine, as in our report.

According to the literature, hospitalization is required in some cases, which did not happen in our case because of the early intervention ([Table 2](#t2){ref-type="table"}).^[@r5]^

###### 

Literature review of case reports about dapsone-induced agranulocytosis in patients with leprosy

                         YEAR   LOCA-    AGE   GEN-   ETHNICITY       TIME UNTIL       CLINICAL                                DIAG-       MANAGEMENT                        CHANGES IN      HOSPI-   OUT-
  ---------------------- ------ -------- ----- ------ --------------- ---------------- --------------------------------------- ----------- --------------------------------- --------------- -------- ----------
  Current paper          2015   Brazil   61    F      Non-Cauca-      After 34 days    Fever                                   \-          Suspension of                     Rifampicin      No       Patient
                                                      sian                             Chills                                              MDT ; Amoxicil-                   and Clofazime            improved
                                                                                       Adynamia                                            lin-Clavulanate;                  Replaces                 after 8
                                                                                       Odynophagia                                         Ciprofloxacin;                    Dapsone;                 days
                                                                                       Paleness                                            Filgastrim                        Ofloxacin +               
                                                                                                                                                                             Rifampicin +              
                                                                                                                                                                             Minocycline               
  Silva *et al.*         2011   Brazil   28    M      Non-Cauca-      before 30 days   Odynophagia                             Severe      Suspension of                     \*              \*       Patient
                                                      sian                             Fever                                   febrile     MDT; broad spec-                                           improved
                                                                                                                               neutro-     trum antibiotic;                                           after 16
                                                                                                                               penia       folic acid                                                 days
  Carneiro *et al.*      2011   Brazil   56    F      Non-Cauca-      After 8 weeks    Odynophagia                             Tonsil-     Suspension of                     Ofloxacin +     Yes      Patient
                                                      sian                             Fever                                   litis       DDS; amoxicil-                    Clofazime +              improved
                                                                                       Dry cough                                           lin clavulanate;                  Minocycline              after 14
                                                                                       Progressive dyspnea                                 Ciprofloxacin;                                             days
                                                                                       Respiratory-dependent                               Cefepime; Oxacil-                                           
                                                                                       chest pain                                          lin; Filgastrim                                             
  Silva *et al.*         2009   Brazil   28    F      Non-Cauca-      After 35 days    Fever                                   Tonsil-     Suspension of                     Restarted       Yes      \*
                                                      sian                             Chills                                  litis       DDS ;Figastrim;                   Rifampicin                
                                                                                       Odynophagia                                         benzathine peni-                  (600mg/                   
                                                                                                                                           cillin; broad spec-               month) and                
                                                                                                                                           trum antibiotic                   Clofazimine               
                                                                                                                                                                             (100 mg/day)              
  Ranawaka *et al.*      2008   Sri      21    M      Non-Cauca-      After 19 weeks   Fever                                   Hemo-       Suspension of                     \*              Yes      Patient
                                Lanka                 sian                             Odynophagia                             lytic       MDT; broad spec-                                           improved
                                                                                                                               anemia      trum antibiotic;                                           after 8
                                                                                                                               and         Filgastrim.                                                days
                                                                                                                               hepatitis   Linezolid; Amik-                                            
                                                                                                                                           acin; Filgastrim; Prednisolone;                             
                                                                                                                                           Vasopressors                                                
                                                                                                                                           Cefotaxime;                                                 
                                                                                                                                           Prednisolone                                                
  Mishra e Chhetia       2006   India    25    M      Non-Cauca-      \*               High fever; Tachypnea;                  Pneu-       Linezolid; Amik-                  \*              Yes      Patient
                                                      sian                             Hypotension; Pharyngeal                 monia       acin; Filgastrim;                                          improved
                                                                                       congestion; Dyspnea;                                Prednisolone;                                              after 7
                                                                                       Cough; Lymphadenopathy                              Vasopressors                                               days
  Bhat e Radhakrishnan   2003   India    60    M      Non-Caucasian   After 21 days    Low fever; Cough; Dyspnea; Chest pain   Pneumonia   Cefotaxime; Prednisolone          \*              Yes      Death

Considering a reduced risk of agranulocytosis development and in accordance with Carneiro *et al.* (2011),^[@r5]^ our aim was not to question DDS therapy for leprosy, but to stimulate clinical awareness of its risks by showing non-specific symptoms of agranulocytosis. We also highlight the need for laboratory test monitoring patients treated with DDS in order to favor the early treatment of this adverse effect, thus enhancing patient prognosis.
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